Sarepta Therapeutics (SRPT) Tops Q3 EPS by 7c

Go back to Sarepta Therapeutics (SRPT) Tops Q3 EPS by 7c

Sarepta (SRPT) Conditional-Approval Thesis Unchanged, Roth Capital Says

November 6, 2015 8:17 AM EST

Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating and $50 price target on Sarepta Therapeutic (NASDAQ: SRPT), saying their conditional-approval thesis remains unchanged.

Chattopadhyay commented, "A new therapy is not considered available therapy if granted accelerated approval based on a surrogate or... More

Needham & Company Maintain High Conviction for Sarepta (SRPT) Eteplirsen Approval

November 6, 2015 6:53 AM EST

Needham & Company analyst Chad Messer reiterated a Buy rating and $50 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying they maintain high conviction in Eteplirsen approval.

Messer commented, "SRPT shares have pulled back from recent highs due to concerns that etelpirsen's later than expected... More

Trading Radar for 11/5: Disney (DIS), Celgene (CELG), SeaWorld (SEAS), Sprouts (SFM), CyberArk (CYBR) Report

November 4, 2015 3:11 PM EST

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Economics:
8:30am EDT

Initial Claims - Street sees 262kContinuing Claims - Street sees 2.145MProductivity: Prelim. - Street sees (0.2%)Unit Labor Costs: Prelim. - Street sees 2.2%

Earnings:

A.M. Castle & Co. (NYSE: CAS) - no Street consensus
ACI Worldwide, Inc. (Nasdaq: ACIW) - consensus EPS $0.11
AES Corp (NYSE: AES) - consensus EPS $0.38
ANSYS... More